Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Accumulated Expenses (2016 - 2025)

Spero Therapeutics filings provide 10 years of Accumulated Expenses readings, the most recent being $5.6 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 2.24% to $5.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.6 million, a 2.24% increase, with the full-year FY2025 number at $5.6 million, up 2.24% from a year prior.
  • Accumulated Expenses hit $5.6 million in Q4 2025 for Spero Therapeutics, down from $5.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $15.3 million in Q3 2024 to a low of $1.3 million in Q1 2024.
  • Median Accumulated Expenses over the past 5 years was $5.7 million (2022), compared with a mean of $6.8 million.
  • The widest YoY moves for Accumulated Expenses: up 622.68% in 2024, down 85.31% in 2024.
  • Spero Therapeutics' Accumulated Expenses stood at $14.4 million in 2021, then plummeted by 59.6% to $5.8 million in 2022, then increased by 13.11% to $6.6 million in 2023, then dropped by 16.79% to $5.5 million in 2024, then increased by 2.24% to $5.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $5.6 million (Q4 2025), $5.6 million (Q3 2025), and $4.2 million (Q2 2025) per Business Quant data.